1. Signaling Pathways
  2. Immunology/Inflammation
    Metabolic Enzyme/Protease
  3. Arginase


Arginase (ARG) is an enzyme involved in urea cycle, where it catalyzes the hydrolysis of L-arginine into L-ornithine and urea. There are two distinct isoforms of arginase, arginase I and II, which are encoded by separate genes and display differences in tissue distribution, subcellular localization, and molecular regulation. Arginase activity has two major homeostatic purposes: first, to rid the body of ammonia through urea synthesis, and second, to produce ornithine, the precursor for polyamines and prolines. Polyamines produced through ornithine decarboxylase (ODC) are necessary for cell proliferation and regulation of several ion channels. Proline produced through ornithine aminotransferase (OAT) is necessary for production of collagen.

Arginase I is a cytosolic enzyme that is abundantly expressed in the liver and plays an essential role in hepatic urea cycle. In contrast, arginase II is a mitochondrial enzyme that is widely expressed outside the liver, most prominently in the kidney and prostate. Arginase functions important for protection against NH3 toxicity and cell growth and repair. Excessive arginase activity in mammals has been associated with cardiovascular and nervous system dysfunction and disease. Two relevant aspects of this elevated activity may be involved in these disease states. First, excessive arginase activity reduces the supply of L-arginine needed by nitric oxide (NO) synthase to produce NO. Second, excessive production of ornithine leads to vascular structural problems and neural toxicity. In addition, Arginase is a potential therapeutic target for the treatment of sexual arousal disorders in men and women.

Arginase Related Products (15):

Cat. No. Product Name Effect Purity
  • HY-101979A
    Numidargistat dihydrochloride
    Inhibitor 98.65%
    Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
  • HY-112885B
    nor-NOHA monoacetate
    Inhibitor 99.96%
    nor-NOHA (Nω-Hydroxy-nor-L-arginine) monoacetate is a potent and selective arginase inhibitor. nor-NOHA monoacetate inhibits rat liver arginase with a Ki of 0.5 µM.
  • HY-19548A
    BEC hydrochloride
    Inhibitor ≥98.0%
    BEC hydrochloride is a slow-binding and competitive Arginase II inhibitor with Ki of 0.31 μM and 30 nM at pH 7.5 and pH 9.5, respectively.
  • HY-15775
    Arginase inhibitor 1
    Inhibitor ≥98.0%
    Arginase inhibitor 1 is a potent inhibitor of human arginases I and II with IC50s of 223 and 509 nM, respectively.
  • HY-W062216
    2-Aminoimidazole is a potent antibiofilm agent that can be used as an adjuvant to antimicrobial. 2-aminoimidazoles disrupts the ability of bacteria to protect themselves by inhibiting biofilm formation and genetically-encoded antibiotic resistance traits. 2-Aminoimidazole is also a weak noncompetitive inhibitor of human arginase I with a Ki of 3.6 mM.
  • HY-155108
    OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study.
  • HY-N11451
    Lacto-N-fucopentaose III
    Lacto-N-fucopentaose III (LNFP-III) is an immune modulator. Lacto-N-fucopentaose III reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation.
  • HY-145331A
    ARG1-IN-1 hydrochloride
    ARG1-IN-1 (example 1) hydrochloride is a human arginase 1 inhibitor with an IC50 of 29 nM.
  • HY-101979
    Inhibitor ≥98.0%
    Numidargistat (CB-1158) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent.
  • HY-N2963
    Broussonin E
    Activator 98.18%
    Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing JAK2-STAT3 signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis.
  • HY-N2237
    Piceatannol 3'-O-glucoside
    Inhibitor 99.87%
    Piceatannol 3'-O-glucoside, an active component of Rhubarb, activates endothelial nitric oxide (NO) synthase through inhibition of arginase activity with IC50s of 11.22 µM and 11.06 µM against arginase I and arginase II, respectively.
  • HY-W010510
    DL-Norvaline, a derivative of L-norvaline, L-norvaline is a non-competitive inhibitor of arginase.
  • HY-112885A
    nor-NOHA acetate
    Inhibitor ≥99.0%
    nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.
  • HY-112868B
    ABH hydrochloride
    ABH (hydrochloride) is a potent arginase inhibitor. ABH (hydrochloride) can be used for researching anti-inflammation.
  • HY-145331
    ARG1-IN-1 (example 1) is a human arginase 1 inhibitor with an IC50 of 29 nM.